163 related articles for article (PubMed ID: 37033336)
1. Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study.
Xiang J; Si J; Hao Y; Wei J; Wang W; Guan Y; Xu C; Song Z
Transl Cancer Res; 2023 Mar; 12(3):550-557. PubMed ID: 37033336
[TBL] [Abstract][Full Text] [Related]
2. Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study.
Shen W; Jin Y; Yu Y; Chen N; Fan Y
Thorac Cancer; 2024 Jan; 15(2):122-130. PubMed ID: 38011005
[TBL] [Abstract][Full Text] [Related]
3. Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
Ning C; Zhang X; Wang Y; Yang X; Yang X; Chao J; Xun Z; Xue J; Wang Y; Sun H; Li Y; Zhang N; Zhu C; Hou X; Sang X; Zhao H
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1461-1471. PubMed ID: 37433375
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review.
Song X; Fan J; Zhu L; Wang Z; He Y; Zhou C
J Thorac Dis; 2021 Aug; 13(8):5093-5103. PubMed ID: 34527346
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study.
Wang W; Lin G; Hao Y; Guan Y; Zhang Y; Xu C; Wang Q; Wang D; Jiang Z; Cai J; Lou G; Song Z; Zhang Y
Eur J Cancer; 2022 Oct; 174():21-30. PubMed ID: 35970032
[TBL] [Abstract][Full Text] [Related]
7. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.
Gao L; Yang X; Yi C; Zhu H
Front Pharmacol; 2019; 10():1173. PubMed ID: 31680957
[No Abstract] [Full Text] [Related]
8. The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis.
He Q; Li J; Zhang C; Tang S; Ren Q
Transl Cancer Res; 2020 Nov; 9(11):6780-6791. PubMed ID: 35117287
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
Jung HA; Kim M; Kim HS; Kim JH; Choi YH; Cho J; Park JH; Park KU; Ku BM; Park S; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2023 Feb; 18(2):223-231. PubMed ID: 36307042
[TBL] [Abstract][Full Text] [Related]
11. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy.
Yang Y; Yu Y; Fan Y; Li H
Biochim Biophys Acta Rev Cancer; 2024 Jun; ():189145. PubMed ID: 38942215
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor myocarditis in thymic epithelial tumors: a case report and literature review.
Feng Y; Zheng P; Zhang W; Yang S; You Y; Chen Y; Ye Y
Transl Cancer Res; 2024 Feb; 13(2):1208-1218. PubMed ID: 38482422
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
Lv W; Pei X; Zhao W; Cong Y; Wei Y; Li T; Zhang H; Lin Z; Saito Y; Kim JJ; Liang Z; Zhong B; Wang Z
Transl Lung Cancer Res; 2022 Feb; 11(2):201-212. PubMed ID: 35280309
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.
Song Z; Lou G; Wang Y; Yang Z; Wang W; Ji Y; Chen S; Xu C; Hu X; Zhang Y
BMC Med; 2022 May; 20(1):154. PubMed ID: 35534877
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
19. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Xu Z; Li T; Hu X; Hao X; Xing P; Li J
Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for thymoma.
Jakopovic M; Bitar L; Seiwerth F; Marusic A; Krpina K; Samarzija M
J Thorac Dis; 2020 Dec; 12(12):7635-7641. PubMed ID: 33447455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]